Evidence map›Paper›PMID 29112648›Full record

ArticleObstetrics and gynecology2017

Cost of Care for the Initial Management of Ovarian Cancer.

Alexandra S Bercow, Ling Chen, Sudeshna Chatterjee, Ana I Tergas, June Y Hou, William M Burke, Cande V Ananth, Alfred I Neugut, Dawn L Hershman, Jason D Wright

Abstract read
In one paragraph

Article in Obstetrics and gynecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Cost of ovarian cancer by the phase of care in the United States.American journal of obstetrics and gynecology · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022
    Article
  12. Article
  13. Article
  14. Employment disruption among women with gynecologic cancers.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alexandra S BercowDepartments of Obstetrics and Gynecology and Medicine and the Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, the Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, and New York Presbyterian Hospital, New York, New York.
Ling Chen
Sudeshna Chatterjee
Ana I Tergas
June Y Hou
William M Burke
Cande V Ananth
Alfred I Neugut
Dawn L Hershman
Jason D Wright

Funding

The Influence of Hospital Variability on the Management of Cancer-Associated CompR01CA169121 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WRIGHT, JASON · 2013 to 2017
$1.8M
Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivorsR01CA166084 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HERSHMAN, DAWN · 2013 to 2016
$1.3M
NCI NIH HHS R01 CA166084NCI NIH HHS R01 CA169121
6 · The paper itself

Abstract

objectiveTo examine the cost of care during the first year after a diagnosis of ovarian cancer, estimate the sources of cost, and explore the out-of-pocket costs.

methodsWe performed a retrospective cohort study of women with ovarian cancer diagnosed from 2009 to 2012 who underwent both surgery and adjuvant chemotherapy using the Truven Health MarketScan database. This database is comprised of patients covered by commercial insurance sponsored by more than 100 employers in the United States. Medical expenditures, including physician reimbursement, for a 12-month period beginning on the date of surgery were estimated. All payments were examined, including out-of-pocket costs for patients. Payments were divided into expenditures for inpatient care, outpatient care (including chemotherapy), and outpatient drug costs. The 12-month treatment period was divided into three phases: surgery to 30 days (operative period), 1-6 months (adjuvant therapy), and 6-12 months after surgery. The primary outcome was the overall cost of care within the first year of diagnosis of ovarian cancer; secondary outcomes included assessment of factors associated with cost.

resultsA total of 26,548 women with ovarian cancer who underwent surgery were identified. After exclusion of patients with incomplete insurance enrollment or coverage, those who did not undergo chemotherapy, and those with capitated plans, our cohort consisted of 5,031 women. The median total medical expenditures per patient during the first year after the index procedure were $93,632 (interquartile range $62,319-140,140). Inpatient services accounted for $30,708 (interquartile range $20,102-51,107; 37.8%) in expenditures, outpatient services $52,700 (interquartile range $31,210-83,206; 58.3%), and outpatient drug costs $1,814 (interquartile range $603-4,402; 3.8%). The median out-of-pocket expense was $2,988 (interquartile range $1,649-5,088). This included $1,509 (interquartile range $705-2,878) for outpatient services, $589 (interquartile range $3-1,715) for inpatient services, and $351 (interquartile range $149-656) for outpatient drug costs.

conclusionThe average cost of care for women with ovarian cancer in the first year after surgery is approximately $100,000. Patients bear approximately 3% of these costs in the form of out-of-pocket expenses.

Indexed as

Ovarian NeoplasmsPatient Care ManagementAdultAgedChemotherapy, AdjuvantCohort StudiesCost AllocationFemaleGynecologic Surgical ProceduresHealth Care CostsHealth ExpendituresHumansMiddle AgedOutcome and Process Assessment, Health CareRetrospective StudiesUnited States

Identifiers

PMID29112648
PMCPMC5709160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.